Alexandra Okmian | Senior Business Development and Investor Relations Manager |
Dror Ben-Asher | Chief Executive Officer |
Guy Goldberg | Chief Business Officer |
Gilead Raday | Chief Operating Officer |
Rob Jackson | Senior Vice President, Sales and Marketing |
Micha Ben-Chorin | Chief Financial Officer |
Rick Scruggs | Chief Commercial Officer |
Adi Frish | Chief Corporate and Business Development Officer |
Bob Gilkin | Senior Vice President, Market Access and Trade Relations |
Boobalan Pachaiyappan | H.C. Wainwright |
Robert Hazlett | BTIG |
David Hoang | SMBC |
Matthew Kaplan | Ladenburg Thalmann |
Scott Henry | ROTH Capital Partners |
Good day, and welcome to the RedHill Biopharma Second Quarter 2021 Financial Results Conference Call. [Operator Instructions] At this time, I would like to introduce to the conference call RedHill's CEO, Dror Ben-Asher; Micha Ben-Chorin, Chief Financial Officer; Rick Scruggs, Chief Commercial Officer; Gilead Raday, Chief Operating Officer; Guy Goldberg, Chief Business Officer; Adi Frish, Chief Corporate and Business Development Officer; Rob Jackson, Senior Vice President, Sales and Marketing; and Bob Gilkin, Senior VP, Market Access and Trade Relations.
Before we begin, we will read from the RedHill's safe harbor statement. Please go ahead.
Thank you, Andrea.